Promomed Group has added a new lung cancer drug to its cancer portfolio

Gefitinib-Promomed used for the treatment of lung cancer has received marketing authorization certificate and became the third drug in the cancer portfolio of Promomed Group

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer with about 80% of all lung cancer cases. Gefitinib-Promomed is a modern tyrosine kinase inhibitor, which is used today in all lines of NSCLC therapy in patients with a mutation in the epidermal growth factor receptor (EGFR) gene.

The efficacy of gefitinib has been studied in several large clinical studies. Randomized study INTEREST was one of the first large-scale studies, in which gefitinib demonstrated good tolerability and clinically significant improvement in the quality of life associated with health in a larger number of patients. The results obtained confirm the safety and efficacy of this drug in patients with NSCLC.

The formation of a portfolio of drugs for the treatment of socially significant diseases including cancer is one of the most important tasks for Promomed Group as part of a strategy to solve global medical problems, save lives and significantly improve the health of patients. When introducing new drugs to the market, including generics, the company offers patients effective and safe drug products through the high quality of substances, the technological effectiveness of production processes, and the highest quality control standards.

Gefitinib-Promomed will be available in the form of 250 mg tablets, which corresponds to standard treatment schemes.

Like most drug products produced by Promomed Group, this drug is included in the list of vital and essential drugs.